AI is revolutionizing drug discovery. But there’s a billion-dollar problem nobody talks about: Making what AI discovers. As artificial intelligence unlocks an entirely new world of molecules and potential medicines, traditional manufacturing may struggle to keep pace. In this @mashable feature, discover how @eXoZymes is working to bridge the gap between AI-powered discovery and real-world production - potentially changing how tomorrow’s medicines are made. Full story on Mashable: na2.hubs.ly/H08sRfL0 $EXOZ

CEO @heltzen was recently interviewed by @PIX11News "Top Leaders" host, @TheNadjaAtwal Michael Heltzen is leading @eXoZymes in rethinking biomanufacturing. By harnessing enzymes and AI, the company aims to produce health ingredients faster, sustainably, and closer to home—reducing reliance on traditional supply chains while making previously inaccessible natural compounds available at scale. Full story available here: na2.hubs.ly/H08gGW40 $EXOZ

WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity @WTR_Research’s new research report takes a close look at how @eXoZymes is moving from a promising scientific platform toward a potentially scalable commercial business. 7 things to know from the report: * eXoZymes is moving from scientific validation toward commercial validation. * NCT has emerged as the company’s key near-term commercial opportunity. * The company has made significant progress in improving the economics of NCT production. * Curia Global is now helping take the technology beyond pilot-scale production. * The report sees substantial longer-term potential in pharmaceutical applications of the platform. * Cannabinoids, santalene and five new molecules add further pipeline optionality. * The next major milestones are scale-up, commercial partnerships and turning technical progress into revenue. For investors looking to understand what has changed at $EXOZ, where the company is heading, and what needs to happen next, the report provides a timely look at the company’s evolving strategy and commercial opportunity. Read the full report here - available with free login! na2.hubs.ly/H088rNs0

Research coverage from @WTR_Research: $EXOZ 2Q26 update - from platform validation to commercial execution - The productivity result is the standout headline, beating management’s own hurdle. - Scale-up and reproducibility have already been demonstrated independently - The business model is becoming increasingly asset-light - The strategy reset should strengthen the negotiating position of @eXoZymes Read the full update here - accessible with a free login: na2.hubs.ly/H07pTT40

eXoZymes' NCT process advances beyond original commercial-scale economic targets The optimized NCT process delivered: 1) a 10-fold improvement in productivity 2) produced approximately 67% more NCT per liter 3) reaction time was reduced by over 80% 4) Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT CCO of @eXoZymes, Damien @Perriman, states, “In less than two years, we have moved NCT from an idea to a biosolution with performance and cost levels placing us beyond our original commercial launch targets. For investors and potential partners, the combination of rapid product development and a fast-declining cost curve is really the story, because it demonstrates how quickly we can progress a product molecule toward commercially relevant manufacturing economics.” All details right here: na2.hubs.ly/H07hvPz0 $EXOZ

“Nature has already created extraordinary molecules. The challenge has never been understanding their value - it’s been accessing them.” ~ Damien @Perriman, CCO, @eXoZymes In this @WebullGlobal presentation, Perriman explains how eXoZymes’ cell-free biomanufacturing platform is designed to change that. From successful 100L third-party manufacturing to a growing pipeline spanning nutraceuticals and pharmaceuticals, we’re focused on turning previously inaccessible molecules into scalable commercial opportunities. Perriman on the status of company and technology: "We believe we’ve crossed from science risk to execution risk." Watch the full presentation right here: na2.hubs.ly/H06m3yB0 $EXOZ

For decades, synthetic biology had to chase big targets - biofuels and commodity volumes - because expensive R&D required massive scale just to recoup costs. That math has changed. And it changes what's worth making. On the Ladder 17 'FoodTech Stories' podcast, our CCO Damien @Perriman makes the case to host Megan Thomas that as AI and enzyme engineering have brought R&D costs down by an order of magnitude, a whole class of valuable molecules that were never worth pursuing is suddenly within reach - especially the natural compounds science already knows do something, but that no one could ever make efficiently - until now. At @eXoZymes, NCT is the proof. It's a compound tied to a key metabolic switch: one that helps regulate how the body uses fat at the mitochondrial level. NCT is long studied, but never commercialized, because it exists in vanishingly small amounts in nature and no one could figure out how to produce it. Using cell-free biomanufacturing, eXoZymes took it from idea to pilot scale in just 11 months. Damien's bigger point is that this is an inflection point for the whole sector. When the cost of trying drops by 10x, you don't need world-changing volume to justify the work. You can finally act on high-value, molecule-driven business cases previously too cost-prohibitive to look at before. Don't miss the full episode: na2.hubs.ly/H06j5jS0 $EXOZ

From the @RollingStone magazine: The cannabis industry is entering its next evolution - shifting from commodity cultivation to the high-value race for rare cannabinoids, novel compounds and scalable biomanufacturing. The winners may not be the companies growing the most cannabis, but the ones that can engineer and manufacture the molecules nobody else can access. Companies like @eXoZymes are helping drive this shift by developing cell-free biomanufacturing platforms designed to produce rare (non-intoxicating) compounds with greater precision, scalability, and efficiency. Read the full article here: na2.hubs.ly/H05wBtl0 $EXOZ

Case study from @Springwise featuring Damien @Perriman: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturing. @eXoZymes takes enzyme pathways from biology and brings them into the world of chemistry. @CaymanChemical is helping to scale this novel approach Full case study available here: na2.hubs.ly/H04Xthr0 $EXOZ

Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen In this episode, John Gagliano of @BPharmCatalyst sits down with Michael @Heltzen, CEO of @eXoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how eXoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market. Full episode available here: na2.hubs.ly/H04RWNw0 $EXOZ #exozymes #exozyme #biomanufacturing

Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. @Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.” Full @messaginglab podcast episode available as both video and audio here: exozymes.com/blog/grow-every… #exozymes #cellfree #biomanufacturing $EXOZ

From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition. Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT. Full story available here: na2.hubs.ly/H04N4_c0

$EXOZ management to host conference call today at 5:30 PM Eastern: na2.hubs.ly/H04CgGV0 Michael @Heltzen, CEO of @eXoZymes (Nasdaq: EXOZ), states, “We’ve moved beyond our ‘big idea’ potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to advance through commercialization milestones.” Full press release on the investor call here: na2.hubs.ly/H04Cmc40 #exozymes #exozyme #enzymes #enzyme #biomanufacturing

As part of @Nasdaq's 'Amplify Spotlight' series, CEO of eXoZymes, Michael Heltzen (@heltzen), recently sat down with Michael B. Spector (@michaelbspector) from Nasdaq for a in-depth interview. Heltzen states: "That's how we can run these simulations much much faster and much cheaper than anyone else and therefore it allows us to to brute force evolution." Full interview available here: exozymes.com/blog/nasdaq-int… $EXOZ @NasdaqExchange #exozymes #exozyme #enzymes #enzyme

Advancing commercial readiness with profound production metrics on initial NCT pilot run: The pilot run achieved approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity at 100L scale. Co-founder of @eXoZymes and VP of Development, Paul Opgenorth (@popgenorth), PhD, states: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend.” Full story here: na2.hubs.ly/H03l_W90 #exozymes #enzymes #nutraceuticals #exozyme #biomanufacturing #enzyme

Good things are in motion. Our CEO @heltzen being interviewed by @michaelbspector at @Nasdaq today. $EXOZ